I don't understand why Sarepta was given accelerated approval and worked closely with the FDA for years and just days before FDA final approval are told that there drug isn't any good. None of this makes any sense. This is exactly why drugs are costing Americans so much money. The FDA could have pulled the plug on this drug months or years ago. If the FDA not doing their job by letting the investors think their drugs are something that could be approved and then at the very end of the process come out and say they will not approve the drug that they have been following for months/years. I also wonder if the Adcoms are a waste of time and money for both the companies and the FDA. Supposedly, the so called experts voted in favor of approval based on the data they got to review. What data did the FDA have that they didn't share with the ADCOM?
I agree that earnings aren't an issue at this point. I guess Adam Frienstien (sp) will have an article out this morning also. This looks like a buying opportunity this morning.
I agree. I heard nothing about any changes to improve shareholder value. They seemed content to ask shareholders to hang on for yet another year to see what, if anything, they are going to do to increase shareholder value. I had never seen the head of the board of directors before and I wasn't impressed at all with him or his communication skills. I believe they needs to be a call to change out the BOD.
Why hasn't anyone told me? If you go to yahoo's 5 day trading chart you can see how a stock is trading premarket. I have never noticed this before.
As far as I know, you can't sell a stock unless there is someone willing to buy it. Someone believes this stock is going back up. We will just have to wait and see that someone is.
This has to be the stupidest post ever. You are saying that people with dementia have the mental capacity to be influenced by a pill. I don't think they understand that they are even taking a pill. Apparently you have never been around a person with dementia.
Adam M. Klein, MD, FACS
Dr. Adam Klein
Adam M. Klein, MD, FACS, who started practicing at Emory in 2005, is Assistant Professor, Otolaryngology – Head and Neck Surgery, at The Emory Voice Center, Emory University Hospital Midtown.
Laryngology (Completed fellowship training in 2005)
Otolaryngology (Board certified in 2005)
Areas of Expertise
Care of the Professional Voice
It bothers me that not one new media outlet has said a word about this. I know it is a weekend but in this age of instant news we should have heard something.